MIM
MRVI icon

MetLife Investment Management’s Maravai LifeSciences MRVI Stock Holding History

MetLife Investment Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$152K Buy
53,588
+10,239
+24% +$34.7K ﹤0.01% 2351
2025
Q4 		$141K Sell
43,349
-15,365
-26% -$51.7K ﹤0.01% 2445
2025
Q3 		$169K Sell
58,714
-17,973
-23% -$45.9K ﹤0.01% 2409
2025
Q2 		$185K Buy
76,687
+29,933
+64% +$62.9K ﹤0.01% 2237
2025
Q1 		$103K Sell
46,754
-28,150
-38% -$111K ﹤0.01% 2512
2024
Q4 		$408K Buy
74,904
+10,168
+16% +$65.4K ﹤0.01% 1909
2024
Q3 		$538K Buy
64,736
+36,476
+129% +$315K ﹤0.01% 1746
2024
Q2 		$202K Buy
28,260
+23,491
+493% +$203K ﹤0.01% 2238
2024
Q1 		$41.3K Buy
4,769
+14
+0.3% +$95 ﹤0.01% 2733
2023
Q4 		$31.1K Sell
4,755
-70
-1% -$452 ﹤0.01% 2796
2023
Q3 		$48.3K Buy
4,825
+3
+0.1% +$33 ﹤0.01% 2836
2023
Q2 		$59.9K Sell
4,822
-1,831
-28% -$24.7K ﹤0.01% 2880
2023
Q1 		$93.2K Buy
6,653
+15
+0.2% +$215 ﹤0.01% 2580
2022
Q4 		$95K Sell
6,638
-174
-3% -$2.74K ﹤0.01% 2615
2022
Q3 		$174K Buy
6,812
+5
+0.1% +$125 ﹤0.01% 2391
2022
Q2 		$193K Sell
6,807
-294
-4% -$9.31K ﹤0.01% 2345
2022
Q1 		$250K Buy
+7,101
New +$238K ﹤0.01% 2216

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

MetLife Investment Management's MRVI Position: Q1 2026 in Review

MetLife Investment Management increased its Maravai LifeSciences (MRVI) stake by 24% in Q1 2026, buying an estimated $34.7K and bringing the position to 53,588 shares worth $152K. The position accounts for ﹤0.01% of the portfolio, ranked #2351.

MetLife Investment Management first reported a position in MRVI in Q1 2022 and has held it in 17 quarters since. The position peaked at $538K in Q3 2024. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • MetLife Investment Management held 53,588 shares of Maravai LifeSciences worth $152K as of Q1 2026.
  • MetLife Investment Management bought 10,239 Maravai LifeSciences shares in Q1 2026, an estimated $34.7K.
  • Maravai LifeSciences made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2351 holding.
  • MetLife Investment Management first reported a position in Maravai LifeSciences in Q1 2022 and has held it in 17 quarters since.
  • MetLife Investment Management's Maravai LifeSciences position peaked at $538K in Q3 2024.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.